Trial site
Urology of Indiana
Greenwood, Indiana 46143, United StatesNot linked to an institution yet
The trials here
What the 7 trials at this site are about, from their registry records.
- Phase
- Phase 33 trials
- Phase 1/22 trials
- Phase 22 trials
- Status
- Active, not recruiting5 trials
- Recruiting2 trials
- Lead sponsor
- Janssen Research & Development, LLC4 trials
- CG Oncology, Inc.1 trial
- enGene, Inc.1 trial
- Tyra Biosciences, Inc1 trial
Running trials
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Contact: Gina Risdall
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Active, not recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: enGene clinical trials
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error